(0.22%) 5 111.31 points
(0.24%) 38 330 points
(0.22%) 15 963 points
(-1.37%) $82.70
(4.26%) $2.01
(0.00%) $2 347.30
(-0.17%) $27.49
(3.68%) $956.00
(-0.16%) $0.933
(-0.25%) $11.00
(-0.46%) $0.797
(1.76%) $93.49
Live Chart Being Loaded With Signals
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection...
Stats | |
---|---|
本日の出来高 | 3 326.00 |
平均出来高 | 705.00 |
時価総額 | 263.19B |
EPS | €0 ( 2024-04-26 ) |
次の収益日 | ( €0 ) 2024-07-25 |
Last Dividend | €1.480 ( 2023-07-13 ) |
Next Dividend | €0 ( N/A ) |
P/E | 58.52 |
ATR14 | €0.794 (0.53%) |
Abbvie Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Abbvie Inc 財務諸表
Annual | 2023 |
収益: | €54.32B |
総利益: | €33.90B (62.42 %) |
EPS: | €2.75 |
FY | 2023 |
収益: | €54.32B |
総利益: | €33.90B (62.42 %) |
EPS: | €2.75 |
FY | 2022 |
収益: | €58.05B |
総利益: | €40.64B (70.00 %) |
EPS: | €6.69 |
FY | 2021 |
収益: | €56.20B |
総利益: | €38.75B (68.96 %) |
EPS: | €6.92 |
Financial Reports:
No articles found.
Abbvie Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€1.410 (N/A) |
€1.410 (N/A) |
€1.480 (N/A) |
€1.480 (N/A) |
€1.480 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.570 | 2016-07-13 |
Last Dividend | €1.480 | 2023-07-13 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 23 | -- |
Total Paid Out | €24.73 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.02 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.61 | |
Div. Directional Score | 7.62 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
NTH.DE | Ex Dividend Knight | 2023-08-25 | Quarterly | 0 | 0.00% | |
AEIN.DE | Ex Dividend Knight | 2023-06-14 | Annually | 0 | 0.00% | |
GOB.DE | Ex Dividend Knight | 2023-06-12 | Sporadic | 0 | 0.00% | |
PSQ.F | Ex Dividend Knight | 2023-08-23 | Semi-Annually | 0 | 0.00% | |
BLQA.DE | Ex Dividend Knight | 2023-09-07 | Quarterly | 0 | 0.00% | |
INH.DE | Ex Dividend Knight | 2023-05-18 | Annually | 0 | 0.00% | |
ST5.DE | No Dividend Player | 2023-06-26 | Annually | 0 | 0.00% | |
CTO.DE | Ex Dividend Knight | 2023-08-24 | Quarterly | 0 | 0.00% | |
LOM.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
2GB.DE | Ex Dividend Junior | 2023-06-14 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0895 | 1.500 | 8.21 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0361 | 1.200 | 8.80 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.400 | 1.500 | 6.66 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 2.17 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0.872 | 0.800 | -0.639 | -0.512 | [1 - 3] |
quickRatioTTM | 0.633 | 0.800 | -0.980 | -0.784 | [0.8 - 2.5] |
cashRatioTTM | 0.339 | 1.500 | 9.23 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.441 | -1.500 | 2.65 | -3.98 | [0 - 0.6] |
interestCoverageTTM | 3.35 | 1.000 | 9.87 | 9.87 | [3 - 30] |
operatingCashFlowPerShareTTM | 12.93 | 2.00 | 5.69 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 12.49 | 2.00 | 3.75 | 7.51 | [0 - 20] |
debtEquityRatioTTM | 5.73 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.624 | 1.000 | 2.93 | 2.93 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.235 | 1.000 | 7.30 | 7.30 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.385 | 1.000 | 8.97 | 8.97 | [0.2 - 2] |
assetTurnoverTTM | 0.403 | 0.800 | -0.645 | -0.516 | [0.5 - 2] |
Total Score | 10.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 58.82 | 1.000 | 4.16 | 0 | [1 - 100] |
returnOnEquityTTM | 0.400 | 2.50 | 7.86 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 12.49 | 2.00 | 5.84 | 7.51 | [0 - 30] |
dividendYielPercentageTTM | 4.70 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 12.93 | 2.00 | 5.69 | 10.00 | [0 - 30] |
payoutRatioTTM | 2.17 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | -1.078 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.420 | 1.000 | 1.988 | 0 | [0.1 - 0.5] |
Total Score | 4.61 |
Abbvie Inc
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。